{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:30:35Z","timestamp":1790217035535,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ijid.2022.08.014","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T02:14:50Z","timestamp":1661220890000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-5884","authenticated-orcid":false,"given":"Xiaoxuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-0309","authenticated-orcid":false,"given":"Lu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.08.014_bib0001","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s11096-020-01072-7","article-title":"Tigecycline-associated hypofibrinogenemia in a real-world setting","volume":"42","author":"Campany-Herrero","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.ijid.2022.08.014_bib0002","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1086\/431675","article-title":"Tigecycline 300 cSSSI Study Group, Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam","volume":"41","author":"Ellis-Grosse","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.08.014_bib0003","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1111\/j.1365-2125.2001.00770.x","article-title":"Best practice in therapeutic drug monitoring","volume":"52","author":"Gross","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2022.08.014_bib0004","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","article-title":"Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients","volume":"76","author":"Hu","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2022.08.014_bib0005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1248\/bpb.35.967","article-title":"Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system","volume":"35","author":"Kadoyama","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.ijid.2022.08.014_bib0006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/14740338.2015.997206","article-title":"Tigecycline: a critical safety review","volume":"14","author":"Kaewpoowat","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ijid.2022.08.014_bib0007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jgar.2021.04.006","article-title":"Dose optimisation based on pharmacokinetic\/pharmacodynamic target of tigecycline","volume":"25","author":"Leng","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijid.2022.08.014_bib0008","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/trf.12431","article-title":"Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy","volume":"54","author":"Levy","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.ijid.2022.08.014_bib0009","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2146\/ajhp150894","article-title":"Tigecycline-induced coagulopathy","volume":"74","author":"McMahan","year":"2017","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijid.2022.08.014_bib0010","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.01084-06","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections","volume":"51","author":"Meagher","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0011","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1093\/jac\/dkz337","article-title":"Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis","volume":"74","author":"Mei","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0012","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0013","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.00813-07","article-title":"Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections","volume":"52","author":"Passarell","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0014","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2020007208","article-title":"Disseminated intravascular coagulation and its immune mechanisms","volume":"139","author":"Popescu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2022.08.014_bib0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/AAC.00277-10","article-title":"Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia","volume":"56","author":"Rubino","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0016","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1345\/aph.1H543","article-title":"Tigecycline: a novel broad-spectrum antimicrobial","volume":"41","author":"Slover","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0018","doi-asserted-by":"crossref","first-page":"e00317","DOI":"10.1128\/AAC.00345-17","article-title":"Population pharmacokinetics of tigecycline in critically ill patients with severe infections","volume":"61","author":"Xie","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.08.014_bib0019","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijid.2013.09.008","article-title":"Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic\/pharmacodynamic analysis of tigecycline by Monte Carlo simulation","volume":"18","author":"Xie","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2022.08.014_bib0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijid.2019.03.011","volume":"82","author":"Xu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2022.08.014_bib0021","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2022.08.014_bib0022","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijid.2022.08.014_bib0023","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/jcpt.13250","article-title":"Risk factors for tigecycline-induced hypofibrinogenaemia","volume":"45","author":"Zhang","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijid.2022.08.014_bib0024","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1111\/bcp.14692","article-title":"Population pharmacokinetics and exposure-response analysis of tigecycline in patients with hospital-acquired pneumonia","volume":"87","author":"Zhou","year":"2021","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222004842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222004842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:08:52Z","timestamp":1761120532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222004842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"alternative-id":["S1201971222004842"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.08.014","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}